ICOO 2018 Keynotes



Elinore McCance-Katz, MD, PhD
Assistant Secretary for Mental Health and Substance Use
Office of the Administrator
Substance Abuse and Mental Health Services Administration (SAMHSA)

   
Elinore McCance-Katz, MD, PhD, the first Assistant Secretary of Health and Human Services for Mental Health and Substance Use is set as Keynote Speaker at the seventh annual International Conference On Opioids. She will articulate how the Federal government has developed a multipronged, long-term strategy to address the opioid crisis. 

   Dr. McCance-Katz obtained her PhD from Yale University with a specialty in Infectious Disease Epidemiology and is a graduate of the University of Connecticut School of Medicine. She is board certified in General Psychiatry and in Addiction Psychiatry. She is a Distinguished Fellow of the American Academy of Addiction Psychiatry with more than 25 years as a clinician, teacher, and clinical researcher. Most recently she served as the Chief Medical Officer for the Rhode Island Department of Behavioral Healthcare, Developmental Disabilities and Hospitals and as the Chief Medical Officer for the Eleanor Slater Hospital system which is Rhode Island's state resource for patients with the most serious mental illnesses and medical illnesses requiring long term, inpatient care. She was also Professor of Psychiatry and Human Behavior at Brown University. Previously, she served as the first Chief Medical Officer for the Substance Abuse and Mental Health Services Administration (SAMHSA). Prior to coming to SAMHSA, she served at the University of California, San Francisco as a Professor of Psychiatry, as the Medical Director for the California Department of Alcohol and Drug Programs, and as the Medical Director of SAMHSA's Clinical Support Systems for Buprenorphine (PCSS-B) and Opioids (PCSS-O).

   Dr. McCance-Katz has published extensively in the areas of clinical pharmacology, medications development for substance use disorders, drug-drug interactions, addiction psychiatry, and treatment of HIV infection in drug users. She served on the World Health Organization (WHO) committee that developed guidelines on the treatment of drug users living with HIV/AIDS. She has been a national leader in addressing the overprescribing of opioid analgesics and in providing consultation on management of patients with chronic pain and opioid overuse. She was a participant in the development of SAMHSA TIP 40 which provided the initial guidance to physicians utilizing buprenorphine in the treatment of opioid use disorder, contributed to the development and maintenance of the legislatively required 8 hours of physician training for prescribing buprenorphine products and has continued to be actively involved in the development and delivery of physician training on office-based treatment of opioid use disorders. She has been one of the architects of Rhode Island's plan for addressing the opioid epidemic including new approaches to treatment in the form of a statewide system of Centers of Excellence in the treatment of opioid use disorder, new approaches to training in the utilization of DATA 2000 (Drug Abuse Treatment Act of 2000) to bring DATA waiver training to medical students, and going forward, nurse practitioner and physician assistant students, and legislative/regulatory work addressing safe use of opioids in acute pain.

Join us in Boston...


Daniel P. Alford, MD, MPH

Professor of Medicine, Associate Dean of Continuing Medical Education
Director of the Safe and Competent Opioid Prescribing Education
(SCOPE of Pain) Program
Boston University School of Medicine. 

Keynote Title: Opioid Prescribing Education: Does it Work?

   Daniel P. Alford, MD, MPH is Professor of Medicine, Associate Dean of Continuing Medical Education and Director of the Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program at Boston University School of Medicine. 
He is on staff in the Section of General Internal Medicine and Director of the Clinical Addiction Research and Education (CARE) Unit at Boston Medical Center.

   Dr. Alford is past-president of the Association for Medical Education and Research in Substance Abuse. In 2011 he was recognized as a “Champion of Change” by the White House. In 2014 he received the AMA “Award for Health Education.”

   In 2016, Dr. Alford was awarded the American Society of Addiction Medicine first “Educator of the Year Award” and the American College of Physicians “Award for Distinguished Contributions to Behavioral Medicine”. His clinical, educational and research interests focus on opioid use disorders and safe and competent opioid prescribing for chronic pain.

...for the best and brightest minds!


Dr. Mark Ware, MBBS MRCP

Associate Professor in Family Medicine and Anesthesia
McGill University
Director of Clinical Research
Alan Edwards Pain Management Unit
McGill University Health Centre
co-Director of the Quebec Pain Research Network
Executive Director
Canadian Consortium for the Investigation of Cannabinoids


   World-renowned pain specialist and medical cannabis researcher Dr. Mark Ware, MBBS MRCP (UK) is a family physician and Associate Professor in Family Medicine and Anesthesia at McGill University. He is the Director of Clinical Research of the Alan Edwards Pain Management Unit at the McGill University Health Centre, co-Director of the Quebec Pain Research Network, and Executive Director of the non-profit Canadian Consortium for the Investigation of Cannabinoids. Since November 1999, he has been working as a pain physician at the Montreal General Hospital.  


   Dr.  Ware lectures extensively on clinical pain management, including pharmacology, complementary approaches to chronic pain and the neurobiology of pain. 

   In the past 10 years Dr. Ware has given numerous lectures across Canada on pain to health care practitioners and the public. He teaches pain medicine and integrative medicine to medical students at McGill and was recently appointed as a McGill Teaching Scholar to coordinate pain education in the medical school curriculum.

   Dr. Ware’s primary research interests are in evaluating the safety and effectiveness of medicines derived from cannabis (cannabinoids), population-based studies of the impact of pain on the population, and complementary therapies in pain and symptom management

Please bookmark this page and check back periodically.
Schedule Subject to change without notice

 ICOO 2018 Conference Times
Saturday June 9, 2018
 Exhibitor Setup 2:30 pm to 5:00 pm
Attendee Registration 2:30 pm to 5:00 pm
Sunday June 10, 2018
Attendee and Exhibitor Registration 7:00 am to 6:00 pm
Conference day begins at 8:00 am -  day ends at 8:00 pm
Monday, June 11, 2018
Attendee and Exhibitor Registration 7:00 am to 5:00 pm
Conference day begins at 8:00 am - day ends at 6:35 pm
Tuesday, June 12, 2018
 Attendee and Exhibitor Registration 7:00am to 1:30pm
 Conference day begins at 8:00 am - 
Conference closes at 12:00 pm
 Exhibit Breakdown 12:00 pm to 4:00pm